Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 4

2(40.0%)

Phase 2

2(40.0%)

Phase 1

1(20.0%)

5Total

Phase 4(2)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05477875Phase 2Completed

Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control

Role: collaborator

NCT04586712Phase 2Completed

Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury

Role: collaborator

NCT05630235Phase 1Recruiting

Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI

Role: collaborator

NCT04603391Phase 4Completed

Cannabidiol and CES1 Interactions in Healthy Subjects

Role: collaborator

NCT05209867Phase 4Completed

Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV

Role: collaborator

All 5 trials loaded